Approccio multidisciplinare per i pazienti ad alto rischio che porta alla diagnosi precoce dei canadesi nello scompenso cardiaco (MAPLE-CHF)
Approccio multidisciplinare per pazienti ad alto rischio che porta alla diagnosi precoce dei canadesi
The goal of this study is improve the screening of heart failure and identify patients early who are at risk of heart failure.
The main question[s] it aims to answer are:
• will an electronic health records (EHR) case finding algorithm for heart failure, followed by N-Terminal pro-brain natriuretic peptide (NT-proBNP) screening and artificial intelligence (AI) echocardiogram compared to usual care identify patients at risk for heart failure earlier than standard of care?
Participants will be enrolled and randomized to either standard of care (SOC) or intervention arm:
SOC arm: electronic health records will be reviewed over six months for assessments performed to identify heart failure.
Intervention arm: blood sample for N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) at local laboratory . For elevated NT-proBNP results (>125pg/ml) an artificial intelligence (AI) echocardiogram and 12 lead electrocardiogram (ECG) will be performed at study site (within 28 days of NT-proBNP result). EHR will be reviewed at six months
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
Heart failure describes a chronic condition where the heart muscle is no longer able to supply the body with enough oxygen and nutrients. This can lead to fatigue and poor quality of life. Often, people do not know they have heart failure until they end up in hospital. This study wants to improve the screening of heart failure and identify patients at risk for heart failure earlier. This will help determine if early-screening and treatment can help prevent further decline in these patients.
This is a randomized, un-blinded study comparing usual care to an intervention group receiving early heart failure testing. Pre-screening will be performed using extracted primary care electronic health records with the case finding algorithm based on the inclusion and exclusion criteria. An invitation letter will be send to prospective patients which include a registration telephone number and link to dedicated study website. The invitation for contact will adopt an "opt out" approach (ask the potential participant to contact the coordinating centre if they do not wish to be contacted).
Potential participants not opting out, or opting in, within 2 weeks of invitation mailing will be sent a patient information package along with follow up contact by research team.
Consented participants will be randomized either to usual care or interventions group and followed for six months. Intervention group will have NT-proBNP drawn and those with an elevated NT-proBNP (>125pg/mL) will have a study visit with assessments to include, physical examination, electrocardiogram and study AI echocardiogram.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Naomi Uchida, BSN
- Numero di telefono: 16048754521
- Email: naomi.uchida@ubc.ca
Backup dei contatti dello studio
- Nome: Jennifer Petterson
- Numero di telefono: 604-875-5104
- Email: jenny.petterson@vch.ca
Luoghi di studio
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1M9
- Reclutamento
- Vancouver General Hospital
-
Contatto:
- Nathaniel Hawkins, MD
- Numero di telefono: 604-875-5264
- Email: nat.hawkins@ubc.ca
-
Sub-investigatore:
- Sean Virani, MD
-
-
Quebec
-
Montreal, Quebec, Canada, H1T 1C8
- Non ancora reclutamento
- Montreal Heart Institute
-
Contatto:
- Anique Ducharme, MD
- Numero di telefono: 3927 514-376-3330
- Email: anique.ducharme@umontreal.ca
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Non ancora reclutamento
- University of Sherbrooke
-
Contatto:
- Serge LePage, MD
- Numero di telefono: 819-349-1788
- Email: serge.lepage@usherbrooke.ca
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Male or female > 40 years of age
-
Informed consent
-
At least two additional risk factors for Heart Failure (HF):
- Coronary artery disease (either a previous documented type 1 myocardial infarction or coronary artery bypass grafting or percutaneous coronary intervention or documented stenosis or an epicardial coronary artery (50% left main stem or >70% left anterior descending, circumflex or right coronary artery)).
- Diabetes type 1 or 2.
- Persistent or permanent atrial fibrillation.
- Previous ischemic or embolic stroke.
- Peripheral artery disease (previous surgical or percutaneous revascularization or documented stenosis >50% of major peripheral arterial vessel.
- Chronic kidney disease (defined as an estimated glomerular filtration rate (eGFR)<60 milliliters per minute (mL/min)/1.73m2 or eGFR 60-90 mL/min/1.73m2 and urine albumin-creatinine ration (UACR) >300mg/g).
- Regular loop diuretic use for >30 days within 12 months prior to consent.
- Chronic obstructive pulmonary disease (COPD) evidenced by one of the following: Pulmonary Function Test (PFT) showing airway obstruction, diagnosis of respiratory physician, CT scan reporting presence of emphysema, or treatment with national guidance advocated COPD therapy.
Exclusion Criteria:
- Inability to give informed consent (e.g. due to significant cognitive impairment).
- Previous diagnosis of heart failure. This is any diagnosis of heart failure with any ejection fraction of any cause.
- Renal replacement therapy.
- Anyone who, in the investigator's opinion, is not suitable to participate in the trial for other reasons e.g., a diagnosis which may compromise survival over the study period.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Selezione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: Investigational arm guided by NT-proBNP result
NT-proBNP drawn and if level elevated (>125 pg/ml) a study visit with artificial intelligence (AI) echocardiogram, electrocardiogram (ECG), and heart failure (HF) focused examination conducted |
blood sample to measure N-terminal prohormone of B-type natriuretic peptide at local laboratory Artificial intelligence driven transthoracic echocardiogram tracing of electrical cardiac activity of the heart basic physiological measurements to include height (cm), weight (kg) and hip circumference (cm) and blood pressure (mmHg) |
|
Nessun intervento: Routine care arm
Participants will be remotely monitored for number of heart failure events |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of participants diagnosed with heart failure (HF) according to the European Society of Cardiology 2021 HF guidelines
Lasso di tempo: enrollment to six months
|
Incidence of HF diagnosis in outpatient settings Urgent heart failure visit. Heart failure hospitalization. |
enrollment to six months
|
|
Number of outpatient HF visits
Lasso di tempo: enrollment to six months
|
Number of outpatient visits for HF with initiation or intensification of oral HF therapy |
enrollment to six months
|
|
Number of urgent HF visit
Lasso di tempo: enrollment to six months
|
Incidence of HF presentation in urgent care setting with administration of intravenous HF therapies |
enrollment to six months
|
|
Number of HF hospitalizations
Lasso di tempo: enrollment to six months
|
Number of admission for HF |
enrollment to six months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
incidence of prescription for guideline recommended HF therapies in patients diagnosed with HFrEF
Lasso di tempo: enrollment to six months
|
number of diagnosis of HF with reduced Ejection Fraction (HFrEF) within 6 months. Patients diagnosed with HFrEF receiving Guideline-directed medical therapy within 6 months |
enrollment to six months
|
|
HF events in HFrEF
Lasso di tempo: enrollment to six months
|
number of HF admissions |
enrollment to six months
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Nathaniel M Hawkins, MD, Associate Professor of Medicine, UBC Division of Cardiology
- Investigatore principale: Anique Ducharme, MD, Professor of Medicine, Univeriste de Montreal, Montreal Heart Institute
- Investigatore principale: Serge LePage, MD, Centre Hospitalier Universite de Sherbrooke-Hopital Fleurimont
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- MAPLE-CHF
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .